{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-032956","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.615729+00:00","generated_at":"2026-06-06T03:36:22.984928+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Benitec Q2 net loss $6.8M; first BB-301 subject cleared DSMB review – enrollment continues","bullets":["Net loss of $6.8M ($2.64 per share) for quarter ended Dec 31, 2023 vs $5.4M ($3.34) a year ago.","Cash and cash equivalents $20.4M at Dec 31, 2023, up from $2.5M at June 30, 2023.","First subject dosed with BB-301 in Nov 2023; DSMB review found no dose-limiting toxicities, recommended continuation without modifications.","23 subjects enrolled in OPMD natural history study; second subject scheduled to receive BB-301 in Feb 2024.","Interim safety and efficacy data from Phase 1b/2a Clinical Treatment Study expected mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-032956","json":"https://secwatch.observer/filing/0001193125-24-032956.json","markdown":"https://secwatch.observer/filing/0001193125-24-032956.md","text":"https://secwatch.observer/filing/0001193125-24-032956.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312524032956/0001193125-24-032956-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312524032956/d756179d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:36:22.984928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e37f684b71ef4e522c405885269d222c405e006","claim":"Benitec Biopharma Inc. reported financial results for fiscal quarter ended December 31, 2023.","evidence_excerpt":"On February 13, 2024, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1808898/000119312524032956/0001193125-24-032956-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal quarter ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}